Leora Horn, MD, MSc, FRCPC

Name: Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum
Start: 2025-09-07T18:30:00+02:00
End: 2025-09-07T19:30:00+02:00

December 21, 2020

|

By

|

Estimated Read Time:

1 minute

Names & News

Leora Horn, MD, MSc, FRCPC, has joined AstraZeneca as the Global Head of Lung Cancer Strategy. Prior to joining AstraZeneca in September 2020, Dr. Horn was an Associate Professor of Cancer Research at Vanderbilt Ingram Cancer Center and Associate Professor of Medicine in the Division of Hematology/Oncology at the Vanderbilt University Medical Center.

About the Authors

Share this Article:

Leora Horn, MD, MSc, FRCPC

Recent Posts

World Conference Conversations: Inside WCLC 2025

Opening Plenary to Highlight Significant Achievements in Thoracic Oncology

Third Annual Amazing Case Race Returns for WCLC 2025

Preconference Workshops Offer Diverse Educational Opportunities Across Specialties

IS03: Satellite EBAC/CME Symposium by Answers in CME: Reshaping the Management of Metastatic NSCLC: Tackling HER2 Overexpression to Elevate Outcomes

Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC